Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

187

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

187 results for “cannabinoids”

Learn how ShareScore rates datasets ↗
ClinicalTrials.gov32/100

PET Imaging of Cannabinoid CB1 Receptors Using [18F]FMPEP-d2

ClinicalTrials.gov study NCT00598286. IPD Sharing: Not stated. Countries: 1. Publications: 3.

restrictedIPD-UNDECIDEDFeb 2026View details →
dryad32/100

Data from: Cannabinoids disrupt memory encoding by functionally isolating hippocampal CA1 from CA3

Open the record for dataset details and reuse information.

publicJun 2018View details →
dryad32/100

Modeling cannabinoids from a large-scale sample of Cannabis sativa chemotypes

Open the record for dataset details and reuse information.

publicAug 2020View details →
zenodo28/100

Figure 3 from: Nocheva H, Sabit Z, Bakalov D, Grigorov E (2021) Interactions between the cannabinoid and the serotonergic systems in modulation of pain perception. Pharmacia 68(1): 109-115. https://doi.org/10.3897/pharmacia.68.e49219

Figure 3 Bidirectional effects of (A) DPAT, (B) AEA, and (C) AEA+DPAT in intact animals and after 1h HS.

opencc-by-4.0Jan 2021View details →
zenodo28/100

Figure 2 from: Nocheva H, Sabit Z, Bakalov D, Grigorov E (2021) Interactions between the cannabinoid and the serotonergic systems in modulation of pain perception. Pharmacia 68(1): 109-115. https://doi.org/10.3897/pharmacia.68.e49219

Figure 2 Effects of CB1-agonist (AEA) and 5НТ1А-agonists (DPAT) alone administration on nociceptive (PP) thresholds in (A) intact animals (int) and (B) animals subjected to 1 hour of heat stress (1h HS) without and after pretreatment with CB1- and 5НТ1А-antagonists (AM and NAN, respectively). PP-thresholds are represented as mean values ± S.E.M. in arbitrary units (AU). ***p < 0.001, **p < 0.01, *p < 0.05 vs. controls. A. +++p < 0.001, ++p < 0.01 vs. int+AEA+DPAT. int+NAN+DPAT were compared to int+DPAT – xxxp < 0.001, xxp < 0.01; int+AM+AEA were compared to int+AEA – $$$ p < 0.001. B. +++p < 0.001, ++p < 0.01 vs. 1h HS; xxxp < 0.001, xxp < 0.01 vs. 1h HS+AEA+DPAT. 1h HS+NAN+DPAT were compared to 1h HS+DPAT – $$$p < 0.001, $$p < 0.01; 1h HS+AM+AEA were compared to 1h HS+AEA – &&&p < 0.001.

opencc-by-4.0Jan 2021View details →
zenodo28/100

Figure 1 from: Nocheva H, Sabit Z, Bakalov D, Grigorov E (2021) Interactions between the cannabinoid and the serotonergic systems in modulation of pain perception. Pharmacia 68(1): 109-115. https://doi.org/10.3897/pharmacia.68.e49219

Figure 1 Effects of CB1- and 5НТ1А-agonists (AEA+DPAT) administration on nociceptive (PP) thresholds in (A) intact animals (int) and (B) animals subjected to 1 hour of heat stress (1 h HS) without and after pretreatment with CB1- and 5НТ1А-antagonists (AM and NAN, respectively). PP-thresholds are represented as mean values ± S.E.M. in arbitrary units (AU). ***p < 0.001, **p < 0.01 vs. controls. A. +++p < 0.001, ++p < 0.01 vs. int+AEA+DPAT. B. +++p < 0.001 vs. 1 h HS; xxxp < 0.001, xxp < 0.01 vs. 1 h HS+AEA+DPAT.

opencc-by-4.0Jan 2021View details →
zenodo28/100

Figure 3 from: Suleymanoglu Y, Bakalov D, Sabit Z, Vodenicharov V, Tafradjiiska-Hadjiolova R, Nocheva H (2024) The endogenous cannabinoid and the adrenergic systems in modulation of stress-response. Pharmacia 71: 1-8. https://doi.org/10.3897/pharmacia.71.e115659

Figure 3 A. Stress (and its many sensory inputs) activates different areas in the brain – the prefrontal cortex (PFC), the thalamus (Thal), the limbic system (LS, comprising the amygdala, hippocampus and hypothalamus), with subsequent adverse effects for the whole organism: fear‐related behaviour, depressive-like conditions, anxiety, helplessness and hopelessness, sleep and feeding disorders; B. Endocannabinoids modulate the activity of pyramidal glutamate neurons and prefrontal glutamatergic plasticity, and have been proved beneficial in decreasing anxiety and depressive-like symptoms, alleviation of fear-conditioned memories, improvement of sleep and feeding.

opencc-by-4.0Jan 2024View details →
zenodo28/100

Figure 2 from: Suleymanoglu Y, Bakalov D, Sabit Z, Vodenicharov V, Tafradjiiska-Hadjiolova R, Nocheva H (2024) The endogenous cannabinoid and the adrenergic systems in modulation of stress-response. Pharmacia 71: 1-8. https://doi.org/10.3897/pharmacia.71.e115659

Figure 2 Effects on r-SIA (1 h RS) estimated by PP-test after A. Clonidine (Clo); B. Desipramine (Des); and C. Yohimbine (Yoh) administrations alone or in combination with anandamide (AEA) / AM251 (AM). Mean values ± S.E.M. are presented in arbitrary units (AU) on the 10th, 20th, 30th, and 40th min after substances administration. A–C ***p < 0.001 vs. controls; +++p < 0.001vs. 1 h RS; xxxp < 0.001vs. A. 1 h RS+Clo; B. 1 h RS+Des; C. 1 h RS+Yoh; xp < 0.05 vs. B. 1 h RS+Des; $$$p < 0.001vs. A. 1 h RS+Clo+AEA; B. 1 h RS+Des+AEA; C. 1 h RS+Yoh+AEA; $p < 0.05 vs. C. 1 h RS+Yoh+AEA.

opencc-by-4.0Jan 2024View details →
zenodo28/100

Figure 1 from: Suleymanoglu Y, Bakalov D, Sabit Z, Vodenicharov V, Tafradjiiska-Hadjiolova R, Nocheva H (2024) The endogenous cannabinoid and the adrenergic systems in modulation of stress-response. Pharmacia 71: 1-8. https://doi.org/10.3897/pharmacia.71.e115659

Figure 1 Effects of AEA on r-SIA estimated by PP-test after one hour of restraint (1 h RS) in rats. Mean values ± S.E.M. are presented in arbitrary units (AU) on the 10th, 20th, 30th, and 40th min after substances administration. ***p < 0.001 vs. controls; +++p < 0.001vs. RS.

opencc-by-4.0Jan 2024View details →
zenodo28/100

Fig. 1 in Cannabinoid-like meroterpenoids from Peperomia incana

Fig. 1. Structures of compounds 1–10 isolated from P. incana.

opennotspecifiedMar 2023View details →
zenodo28/100

Fig. 2 in Cannabinoid-like meroterpenoids from Peperomia incana

Fig. 2. COSY, key HMBC, and NOE correlations of compounds 1–10.

opennotspecifiedMar 2023View details →
zenodo28/100

A photoswitchable cannabinoid for precision treatment of refractory seizures in a mouse epilepsy model

Open the record for dataset details and reuse information.

opencc-by-4.0Aug 2024View details →
zenodo28/100

Cannabinoids vs. whole metabolome: Relevance of cannabinomics in analyzing Cannabis varieties

<p><em>Cannabis sativa</em> has a long history of domestication both for its bioactive compounds and its fibers. This has produced hundreds of varieties, usually characterized in the literature by chemotypes, with &Delta;<sup>9</sup>-THC and CBD content as the main markers. However, chemotyping could also be done based on minor compounds (phytocannabinoids and others). In this work, a workflow, which we propose to name cannabinomics, combines mass spectrometry of the whole metabolome and statistical analysis to help differentiate <em>C. sativa</em> varieties and deciphering their characteristic markers. By applying this cannabinomics approach to the data obtained from 20 varieties of <em>C. sativa</em> (classically classified as chemotype I, II, or III), we compared the results with those obtained by a targeted quantification of 11 phytocannabinoids. Cannabinomics can be considered as a complementary tool for phenotyping and genotyping, allowing the identification of minor compounds playing a key role as markers of differentiation.</p>

opencc-by-4.0Aug 2021View details →
ClinicalTrials.gov28/100

Neural Mechanisms of Cannabinoid-impaired Decision-Making in Emerging Adults

ClinicalTrials.gov study NCT03944954. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov28/100

Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea

ClinicalTrials.gov study NCT04091789. IPD Sharing: NO. Countries: 1. Publications: 15.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov28/100

A Direct-to-Consumer Study Investigating the Effect of Specific Cannabinoid Products on Motivation, Energy Level, Focus, and Appetite in Healthy Adults

ClinicalTrials.gov study NCT06213064. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

Improvement of Quality of Life by Cannabinoids in Oncologic Patients

ClinicalTrials.gov study NCT06097533. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

CANnabinoids in Pediatric ONCology

ClinicalTrials.gov study NCT05754840. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

Opioid and Cannabinoid Interactions

ClinicalTrials.gov study NCT03705559. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov28/100

Brain Imaging of Cannabinoid Receptors

ClinicalTrials.gov study NCT03204305. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record